BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會

≡

論壇議程總覽

2025 創新科技論壇

​​

2025 Innovation Forum Agenda

Date July 23-25, 2025

Venue July 23 Room 701C, 7F, TaiNEX2
July 24-25 Room 401, 4F, TaiNEX1

Day 1 - Wednesday, July 23Room 701C, 7F, TaiNEX2
Day 2 - Thursday, July 24Room 401, 4F, TaiNEX1
Day 3 - Friday, July 25Room 401, 4F, TaiNEX1

14:10 – 15:40

Session A-1 – New Therapeutic Modalities

Session A-1 is a deep dive into the latest therapeutic innovations, showcasing next-generation approaches reshaping modern medicine. Speakers will present translational breakthroughs in targeted therapies, as well as cutting-edge developments in nucleic acid therapeutics, spotlighting their potential in precision medicine. Other topics covered include accelerating therapeutic pipelines from lab to market, and the latest oncology and hematology therapies. This session promises a dynamic exchange on how novel modalities are redefining treatment landscapes and improving patient care worldwide.
14:10 – 14:15

Opening Remarks

  • Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
14:15 – 14:35

The N of 1 Gene Editing is Here: Lessons on Technology Readiness for Scale-Up

14:35 – 14:55

Driving mRNA Manufacturing Activity in Singapore

  • Boon Tong Koh, Executive Director, Bioprocessing Technology Institute (BTI); Chief Industry Officer, Biomedical Research Council (BMRC), A*STAR
14:55 – 15:15

The Evolving Landscape of Antibody Drug Conjugates (ADC/RDC)

15:15 – 15:35

Taking an ADC into the Cancer Clinic: Medical Considerations

15:35 – 15:40

Closing Remarks

  • Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

16:00 – 17:30

Session A-2 – Gene and Cell Therapies- Advanced Manufacture and Beyond

Session A-2 explores the rapidly-evolving frontier of gene and cell therapy manufacturing, focusing on innovation, scalability, and regulatory alignment. Topics covered will include Taiwan’s strategic role in next-gen biomanufacturing; technical breakthroughs driving production efficiency and therapeutic consistency; addressing the balance between fast-paced technology and regulatory rigor; and an examination of the field of clinical translation and real-world applications. This session promises a comprehensive look at how manufacturing is adapting to meet the complex demands of advanced therapies.
16:00 – 16:05

Opening Remarks

16:05 – 16:20

Topic TBC

  • Ann Lee, Chief Technical Officer, Prime Medicine
16:20 – 16:35

Overcoming Allogenic Immune Rejection

16:35 – 16:50

Opposites Attract: Fast Technology & Deliberate Regulatory: How can manufacturing adapt to meet therapeutic demand?

16:50 – 17:05

Tumor Infiltrating Lymphocytes: Advancing Cell Therapy for Solid Tumors

17:25 – 17:30

Panel Discussion

Moderator:

Panelists:

  • Ann Lee, Chief Technical Officer, Prime Medicine
  • Snehal Patel, Chief Technical Officer, Sana Biotechnology
  • Matthew Hewitt, Vice President, CTO Manufacturing Business Division, Charles River Laboratories
  • Jeffrey Chou, Senior Vice President, Clinical Science, Iovance Biotherapeutics

09:00 – 10:30

Session A-3 – AI & Translational Medicine

Session A-3 spotlights the transformative role of AI in accelerating translational medicine and drug discovery. Speakers will uncover how to better integrate AI in biomedical research; how machine learning enhances cross-dataset drug discovery; AI’s potential in population-level healthcare; and an examination of data-driven public health strategies. Join us as thought leaders demonstrate how AI is reshaping research, improving precision, and bridging discovery to clinical application in unprecedented ways.
09:00 – 09:05

Opening Remarks

09:05 – 09:25

AI-Powered Alignment of High-Content Screening Data: Accelerating Drug Discovery Through Cross-Dataset Learning

09:25 – 09:45

Topic TBC

09:45 – 10:05

Topic TBC

  • Feng-Chi Chen, Executive Director, Forum & Deputy Director and Investigator, Institute of Population Health Sciences, National Health Research Institutes
10:05 – 10:30

Panel Discussion

Moderator:

Panelists:

10:40 – 12:15

Session A-4 – Taiwan BIO Awards-Successful Stories

Join us as this year's Taiwan BIO Awards winners across all categories present their companies and innovations, and unveil the secrets to their success! Congratulations to all this year's well-deserved winners.
10:40 – 12:15

Sharing the Experience of Biotech Success 2025 Taiwan BO Awards Winners:

- Outstanding Company of the Year

- Emerging Company of the Year

- Startup of the Year

- Innovation of the Year

12:25-13:55

Session A-5 – CMC Program Design: Pioneering Biologics Development Excellence

Session A-5 delves into strategic Chemistry, Manufacturing, and Controls (CMC) program design as the cornerstone of biologics development success. Experts from across the biopharmaceutical value chain will explore best practices for building robust, scalable, and regulatory-compliant CMC frameworks that accelerate biologic innovation from early development through commercialization. The session will highlight the integration of advanced analytics, platform technologies, and quality-by-design principles to streamline development timelines while ensuring product integrity and global market readiness. With a focus on collaboration between R&D, manufacturing, and regulatory teams, this session will offer a roadmap for achieving excellence and agility in today’s competitive biologics landscape.
12:25 – 12:30

Opening Remarks

  • Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals
12:30 – 12:50

Topic TBC

12:50 – 13:10

Topic TBC

  • Jennifer Kuan, Vice President of Taiwan Operations, Bora Pharmaceuticals
13:10 – 13:30

Topic TBC

  • Speaker Inviting, Shine On Bio
13:30 – 13:50

Topic TBC

13:50 – 13:55

Closing Remarks

  • Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals

14:10 – 15:30

Session A-6 – Innovative Developments and Cross-Disciplinary Applications of Antibody Derivatives

Session A-6 will explore the expanding frontier of antibody derivatives, showcasing how innovation is unlocking new therapeutic and diagnostic possibilities. Experts will uncover cutting-edge advances in antibody-drug conjugates, bispecifics, nanobodies, and engineered antibodies, highlighting their enhanced specificity, efficacy, and versatility. The session will also examine how these novel formats are being applied beyond oncology, including in infectious diseases and autoimmune disorders. With an emphasis on cross-sector collaboration and real-world applications, this session promises a comprehensive view of how antibodies and antibody derivatives are delivering solutions to complex clinical challenges.
14:10 – 14:15

Opening Remarks

  • Lee-Cheng Liu, Founder, Chairman & President, EirGenix
14:15 – 14:40

TOPIC

  • EirGenix
14:40 – 15:05

Reimagining ADC Design via GlycOBI®: A Multi-Platform Technology for Site-Specific and Dual-Payload Conjugates

  • David Huang, Head of ADC Enabling Technologies and Medicinal Chemistry, OBI Pharma
15:05 – 15:30

TOPIC

  • Boon Tong Koh, Executive Director & Chief Industry Officer at Bioprocessing Technology Institute, BioMedical Research Council, A*STAR (TBD)

15:40 – 17:10

Session A-7 – Innovative Developments and Cross-Disciplinary Applications of Antibody Derivatives

A follow on from Session A-6, again on fast-evolving antibody derivative technologies and their transformative potential across a wide range of therapeutic areas. 
15:40 – 16:05

Immunocytokines: Bridging Antibody Specificity with Cytokine Efficacy for Precise Immune Modulation

  • Ming-Tang Chen, Senior Director, PharmaEssentia
16:05 – 16:30

T-cube, A Non-CD3-Based T Cell Engager Bispecific Antibody Platform with a Favorable Safety Profile

16:30 – 17:10

Panel Discussion

Moderator:
Lee-Cheng Liu, Founder, Chairman & President, EirGenix
Heidi Wang, CEO, OBI Pharma

Panelists:

  • Manuel Sanz, COO, Oncomatryx Biopharma
  • EirGenix
  • Edward Y. H. Hsieh, R&D VP, Formosa labs
  • David Huang, Head of ADC Enabling Technologies and Medicinal Chemistry, OBI Pharma
  • Ming-Tang Chen, Senior Director, PharmaEssentia
  • Jeng Her, CEO, AP Biosciences

09:00 – 10:30

Session A-8 – Novel ADC-based Target Therapy

Session A-8 focuses on the rapid evolution of antibody-drug conjugates (ADCs) as a next-generation targeted therapy category. Experts will highlight innovations in linker chemistry, payload design, and tumor-specific targeting, leading to impressive ADC efficacy and safety profiles. The session will explore how novel ADCs are expanding beyond oncology into new therapeutic areas, offering highly selective treatment options with minimized systemic toxicity. Join us for this important session as leading experts in this field underscore ADCs’ growing role in redefining targeted therapies and improving patient outcomes.
09:00 – 09:05

Opening Remarks

  • Tsai-Kun Li, Vice President, Development Center for Biotechnology
09:05 – 09:25

Topic TBC

  • Teiji Wada, Head of Research Platform and Vice President of Research Innovation Planning Department, Daiichi Sankyo
09:25 – 09:45

LYSward: An Engineering Platform for Generation of pH-Dependent Antibody Drug Conjugate to Enhance Antitumor Activity

  • Yu-Hsun Lo, Director of Protein Engineering Department, Institute of Biologics, Development of Center for Biotechnology
09:45 – 10:05

Regulatory and Scientific Considerations for ADC Bioanalysis

  • Luke BI, Executive Director, Head of China BioA and APAC LCMS, Labcorp
10:10 – 10:30

Panel Discussion

Moderator:

  • Tsai-Kun Li, Vice President, Development Center for Biotechnology

Panelists:

  • Teiji Wada, Head of Research Platform and Vice President of Research Innovation Planning Department, Daiichi Sankyo
  • Yu-Hsun Lo, Director of Protein Engineering Department, Institute of Biologics, Development of Center for Biotechnology
  • Luke BI, Executive Director, Head of China BioA and APAC LCMS, Labcorp
  • Edward Y. H. Hsieh, R&D VP, Formosa labs

10:45 – 12:15

Session A-9 – Smart HealthCare

Session A-9 will explore the transformative impact of smart healthcare technologies on the entire healthcare delivery spectrum, beginning with a discussion on reshaping the future of healthcare through "Gen" medicine, emphasizing precision therapies and personalized treatments. Experts from the TMU Health System will share insights into AI applications in clinical practice, highlighting advancements in diagnostics, treatment planning, and patient monitoring. The session will also address the critical role of AI-driven cybersecurity in safeguarding healthcare systems. A regulatory overview will be provided on the latest FDA guidelines for smart healthcare and AI-based medical devices, ensuring compliance and innovation in this rapidly evolving field.
10:45 – 10:50

Opening Remarks

10:50 – 11:05

Reshaping the Future Healthcare with “Gen” Medicine

11:05 – 11:20

AI Applications in Clinical Practice: Insights from TMU Health System (TBC)

  • Mai-Szu Wu, President, Taipei Medical University
11:20 – 11:35

AI-Driven Cybersecurity in Healthcare Systems (TBC)

  • Wei-Bin Lee, CEO of the Hon Hai Research Institute and the Director of the Information Security Research Center, Hon Hai Technology Group (Foxconn®)
11:35 – 11:50

From Smart to Approved: FDA’s Roadmap for AI-Enabled Medical Devices

11:50 – 12:15

Panel Discussion

Moderator:

Panelists:

  • Ray-Jade Chen, Chairman, Board of Trustees, Taipei Medical University; Chair Professor, Taipei Medical University, Taiwan
  • Mai-Szu Wu, President, Taipei Medical University
  • Wei-Bin Lee, CEO of the Hon Hai Research Institute and the Director of the Information Security Research Center, Hon Hai Technology Group (Foxconn®)
  • Chia-Hua Maggie Ho, COO, Amarex Taiwan

12:25 – 13:55

Session A-10 – Global Trends and Clinical Applications of Whole Genome Sequencing

With the rapid advancement of next-generation sequencing (NGS) technologies, national-scale whole genome sequencing (WGS) initiatives are transforming healthcare, public health, and drug development. This session explores international efforts in building human WGS databases, the strategic roles of key industry players, and the real-world impact of WGS on precision medicine and therapeutics. Experts from leading technology and pharmaceutical companies, along with clinical and regulatory professionals, will provide insights into how WGS data is shaping the future of personalized healthcare.
12:25 – 12:35

Opening Remarks

  • Dr. Chien-Cheng Tai, Senior Technical Specialist of the Department of Industrial Technology, Ministry of Economic Affairs (MOEA)
  • Jeffrey Dutton, Commercial Officer, American Institute in Taiwan (AIT)
  • Eric Y. Chuang, Vice President of ITRI, and General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI

Group Photo

12:35 – 13:23

AI-Driven Multi-Omics and Biobank Partnerships: Accelerating Innovation in Drug Discovery

  • Guillermo Del Angel, Executive Director, Rare Disease therapy area head, Center for Genomics Research, AstraZeneca

The Value of WGS Data in Drug Discovery and Development

  • Kyle Kai-How Farh, Vice President and Distinguished Scientist, Artificial Intelligence, Illumina

Transforming Precision Medicine with AI and Big Data

  • Eric Y. Chuang, Vice President, ITRI, and General Director, BDL, ITRI

Precision Health Meets Global Capital: Opportunities and Risks in a Data-Driven Era (TBD)

  • Dave Whelan, Venture Consultant and Chief Business Officer, Wavemaker 360 Health and Big4Bio
13:23 – 13:50

Panel Discussion: From Global Vision to Local Possibilities: Exploring the Future of WGS in Taiwan

Moderator:

  • Eric Y. Chuang, Vice President of ITRI, and General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI

Panelists:

  • Guillermo Del Angel, Executive Director, Rare Disease therapy area head, Center for Genomics Research, AstraZeneca
  • Kyle Kai-How Farh, Vice President and Distinguished Scientist, Artificial Intelligence, Illumina
  • Wayne Huey-Herng Sheu, Vice President, National Health Research Institutes
  • Dave Whelan, Venture Consultant and Chief Business Officer, Wavemaker 360 Health and Big4Bio

14:10 – 17:00

Session A-11 – Special Session: Digital Health

Session A-11 will provide a comprehensive overview of the latest advancements and trends in digital health, focusing on innovative technologies shaping the future of healthcare delivery. Experts will examine the integration of wearables, mobile health apps, telemedicine, and AI-driven solutions to enhance patient care, improve outcomes, and optimize healthcare systems. The session will face up to challenges such as data privacy, regulatory hurdles, and ensuring equitable access to digital health tools. Special attention will be given to the potential of digital health in transforming chronic disease management, remote patient monitoring, and personalized treatments. Don't miss what promises to be a pivotal discussion of digital health ecosystems, both now and in the future. 
14:10 – 14:20

Opening Remarks

  • Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025
  • Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
14:20 – 14:40

National-Level Investments in Building the Precision Healthcare Industry

  • Chin-Ching Liu, Minister, National Development Council (Inviting)
14:40 – 15:00

Leveraging Health Big Data to Develop Diverse Smart Healthcare Solutions

  • Chung-Liang Shih, Director General, National Health Insurance Administration, Ministry of Health and Welfare
15:00 – 15:20

Smart Healthcare Cloud Ecosystem: Technology Integration and Future Prospects

  • Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
15:20 – 15:35

Topic TBC

  • Yommei Yanagiba, GE HealthCare China Business Development Head and Treasurer, President, HealthCare Financial Services China
15:35 – 15:50

Topic TBC

  • Tony Lee, Head of Sales, Google Cloud
15:50 – 16:05

5G and IoT-Driven Smart Health Solutions

  • Chee Ching, President, Far EasTone Telecom
16:05 – 16:20

Breakthrough Applications and Challenges of AI in Smart Healthcare (TBD)

  • Edward Hsu, President and Chief Medical Officer, Acer Medical
16:20 – 16:35

Topic TBC

  • Ed Deng, Co-Founder and CEO, Health2Sync
16:35 – 16:50

Digital Transformation of Pharmaceutical Sales to Enhance Operational Efficiency

  • Nick Hung, Executive Vice President of Technology and Transformation, Deloitte Taiwan
16:50 – 17:30

Panel Discussion

Moderator:

  • Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025

Panelists:

  • Chin-Ching Liu, Minister, National Development Council (Inviting)
  • Chung-Liang Shih, Director General, National Health Insurance Administration, Ministry of Health and Welfare
  • Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
  • Yommei Yanagiba, GE HealthCare China Business Development Head and Treasurer, President, HealthCare Financial Services China
  • Tony Lee, Head of Sales, Google Cloud
  • Chee Ching, President, Far EasTone Telecom
  • Edward Hsu, President and Chief Medical Officer, Acer Medical
  • Ed Deng, Co-Founder and CEO, Health2Sync
  • Nick Hung, Executive Vice President of Technology and Transformation, Deloitte Taiwan

13:30 – 15:35

Session A-12 – Alzheimer’s Disease Forum

Session A-12  will provide a comprehensive exploration of Alzheimer’s Disease through the perspective of government, caregivers, academia, and industry. Featuring 13 local and international speakers, the session will deliver insights on current disease management, local policy initiatives, and the evolving landscape of treatment development--from historical milestones to next-generation therapeutics. Session speakers will also highlight advances in diagnostic imaging including PET, discuss key pathological indications, and consider the real-world impact on patients and caregivers. This multi-perspective dialogue aims to foster collaboration and innovation toward more effective interventions and support systems in the fight against Alzheimer’s Disease. See you there!
13:30 – 13:35

Opening Remarks & Official Group Photo

  • Jen-Der Lue, Deputy Minister, Ministry of Health and Welfare
13:35 – 13:40

Keynote Speech: The Current Status of Dementia

  • Shih-Chia Lin, CEO, Foundation of Medical Professionals Alliance in Taiwan (FMPAT)
13:40 – 13:50

Landscape and National Policy Framework for Dementia in Taiwan

  • TBA, Ministry of Health and Welfare
13:50 – 14:00

Alzheimer’s Disease

  • Jung-Lung Hsu, Chairman, Taiwan Dementia Society
  • Chief, Department of Neurology, New Taipei Municipal TuCheng Hospital
14:00 – 14:15

History and Current Achievements in Developing beta-Amyloid Centric Treatments for Alzheimer’s Disease

  • TBA, Pharmaceutical Company
14:15 – 14:20

Session 1: Development of Next Generation Diagnostic Technologies for Alzheimer’s Disease

  • Ming-Kuei Jang, CEO, APRINOIA Therapeutics and APN Lifesciences, Taiwan
14:20 – 14:35

Development and Clinical Utilities of Molecular Imaging Probes for Neurodegenerative Diseases

  • Makoto Higuchi, Director, Advanced Neuroimaging Center, QST, Japan
  • Professor, Osaka Metropolitan University School of Medicine, Japan
14:35 – 14:50

Advancement of Brain PET Imaging Acquisition Technologies

  • Taiga Yamaya, Group Leader, Imaging Physics Group
  • Deputy Director, Department of Advanced Nuclear Medicine Sciences, QST, Japan
14:50 – 15:00

Development of Blood-based Diagnostics with BioChips Reaction (BCR) Platform

  • Lu-Yi Lu, CEO, Novascope Diagnostics, Taiwan
15:00 – 15:05

Session 2: Development of Next Generation Treatments for Alzheimer’s Disease

  • Ming-Kuei Jang, CEO, APRINOIA Therapeutics and APN Lifesciences, Taiwan
15:05 – 15:10

Removing Brain Pathologies with Immunotherapy and Protein Degraders

  • Ming-Kuei Jang, CEO, APRINOIA Therapeutics and APN Lifesciences, Taiwan
15:10 – 15:20

Clearance of Brain Pathologies via Astrocytes

  • Sanghoon Park, CEO, Illimis Therapeutics, Korea
15:20 – 15:30

Suppression of Microglia-Mediated Neuroinflammation

  • Hung-Kai Kevin Chen, CEO, Elixiron Immunotherapeutics, Taiwan
15:30 – 15:35

Closing Remarks

  • Shih-Chia Lin, CEO, Foundation of Medical Professionals Alliance in Taiwan (FMPAT)
Session Synopsis

Management of Alzheimer’s Disease from Perspectives of Government, Care Givers, Academy, and Industry